No Data
No Data
Keji Pharmaceutical-B grants 260,000 share options and 60,000 restricted share units
Keji Pharmaceutical-B (02171) issued an announcement. On May 7, 2024, the company granted 260,000 share options to three share option grantees in accordance with the terms of the initial public offering after-sales share option plan, but only after acceptance by the share option grantor. The exercise price for which the share options were granted was HK$5.94 per share. On May 7, 2024, the company granted 60,000 restricted share units to a restricted share unit grantor in accordance with the terms of the restricted share unit after sale of the initial public offering plan, subject to acceptance by the restricted share unit grantor.
Keji Pharmaceutical-B (02171) grants 260,000 share options and 60,000 restricted share units
Keji Pharmaceutical-B (02171) issued an announcement. On May 7, 2024, the company purchased after sales in accordance with the initial public offering...
Keji Pharmaceutical-B (02171): Abstracts of Sikaize and CT071 will be presented separately in oral presentations and posters at the upcoming 2024 EHA Annual Meeting
According to Zhitong Finance App News, Keji Pharmaceutical-B (02171) announced that abstracts of Saikaize (Zewokie Orense injection, product number: CT053, an autologous CAR-T product targeting BCMA) and CT071 (an autologous CAR-T cell candidate product targeting G protein-coupled receptor C group 5 member D (GPRC5D)) have been received for separate oral reports and poster presentations at the 29th European Association of Hematology (EHA) Annual Meeting. According to reports, Cykaize is a whole-person anti-autologous BCMA CAR-T for the treatment of recurrent or refractory multiple myeloma
CARsgen Submitted Responses to FDA Observations
SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancie
Keji Pharmaceutical-B (02171.HK): Submission of a rectification report on FDA findings
Gelonghui, April 29 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The rectification report on the Corrective and Preventive Measures (CAPAs) plan has been submitted to the US Food and Drug Administration (FDA). This submission relates to findings in Form 483 issued by the FDA after an inspection of the clinical production site in Tulham, North Carolina in December 2023. The relevant work is progressing smoothly according to the schedule previously submitted. The company promises to work closely with the FDA to prioritize quality and ensure the production of clinical trial products.
Hong Kong stocks closed (04.25) | Hang Seng Index closed up 0.48%, domestic housing stocks showed strong performance and fell more than 12% after New Oriental-S (09901) results
The Zhitong Finance App learned that the three major indices of Hong Kong stocks had mixed ups and downs. The Hang Seng Index rebounded for four consecutive trading days. After opening slightly lower in early trading, it quickly rose and turned red. The intraday high was 17,434 points to a new high during the new year, then the increase narrowed, showing a volatile adjustment trend. At the close, the Hang Seng Index rose 0.48% or 83.27 points to 17,284.54 points, with a full-day turnover of HK$119.12 billion; the Hang Seng State-owned Enterprises Index rose 0.33% to 6120.37 points; and the Hang Seng Technology Index fell 0.54% to 3554.3 points. CCB International previously indicated that as the Hang Seng Index stabilized its previous low in late January (20
No Data